The shoulder system received FDA clearance in March, and a commercial launch is planned for later this year, according to the May 5 news release. The single-tray arthroplasty system maximizes efficiency and bone preservation, Catalyst said.
“These first surgeries with our Archer R1 reverse system went well, and we’re excited by the feedback we’re getting from the initial surgeon users,” Catalyst chair and CEO Brian Hutchinson said.
